Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Indian Pharmas Seen Bearing Brunt Of U.S. FDA Safety Crackdown

This article was originally published in PharmAsia News

Executive Summary

India's pharmaceutical industry is growing concerned over the recent strong actions taken by U.S. FDA against some Indian-made drugs. Although the European Union and India's own drug regulator have stepped in to block certain Indian drugs, local drug makers say they are being singled out by U.S. authorities. The Indian industry has about 75 plants approved by the U.S. agency, but a new emphasis on use of generics in the United States has led its drug-safety agency to increase its efforts to ensure the safety of those types of drugs. Avesthagen founder Villoo Morawela-Patell said Indian pharmas should expect more U.S. FDA inspections of their plants in India. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts